Dermatology Reports (Sep 2016)

Erythrodermic psoriasis treated with apremilast

  • John Arcilla,
  • Daniel Joe,
  • Johnathan Kim,
  • Yohanan Kim,
  • VuAnh N. Truong,
  • Navin Jaipaul

DOI
https://doi.org/10.4081/dr.2016.6599
Journal volume & issue
Vol. 8, no. 1

Abstract

Read online

Erythroderma is a rare potentially deadly exfoliative dermatitis characterized by diffuse cutaneous erythema which may be associated with multi-organ dysfunction. Therefore, it is imperative to recognize and treat it promptly. Erythrodermic psoriasis is the most common form of erythroderma. Management of this condition is largely based on aggressive supportive care and the use of anti-inflammatory immunosuppressive and biologic agents. We describe a case of psoriatic erythroderma which was triggered by withdrawal from systemic steroids and successfully treated with apremilast and cyclosporine. Apremilast induced atrial fibrillation limited its continued use after the initial response period.

Keywords